CPhI & P-MEC China gives a glimpse of the success returning pharma events will deliver in 2021
The fully launched MAH and priority review pathways from the NMPA (National Medical Products Administration) is stimulating new demand in China for 2021.
The fully launched MAH and priority review pathways from the NMPA (National Medical Products Administration) is stimulating new demand in China for 2021.
沪ICP备05034851号-34